|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
CA2892529C
(en)
|
2012-11-26 |
2023-04-25 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
|
HK1217215A1
(zh)
|
2013-01-17 |
2016-12-30 |
Modernatx, Inc. |
用於改变细胞表型的信号传感器多核苷酸
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
DK4023249T3
(da)
|
2014-04-23 |
2025-01-13 |
Modernatx Inc |
Nukleinsyrevacciner
|
|
DK4023755T5
(da)
|
2014-12-12 |
2024-07-29 |
CureVac SE |
Kunstige nukleinsyremolekyler til forbedret proteinudtrykkelse
|
|
WO2016100812A1
(en)
*
|
2014-12-19 |
2016-06-23 |
Moderna Therapeutics, Inc. |
Terminal modifications of polynucleotides
|
|
EP4218805A1
(en)
|
2015-07-21 |
2023-08-02 |
ModernaTX, Inc. |
Infectious disease vaccines
|
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
|
US12150980B2
(en)
|
2015-07-30 |
2024-11-26 |
Modernatx, Inc. |
Concatemeric peptide epitope RNAs
|
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
CA3001003A1
(en)
|
2015-10-05 |
2017-04-13 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
WO2017070624A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Tropical disease vaccines
|
|
MA52645B1
(fr)
|
2015-10-22 |
2022-06-30 |
Modernatx Inc |
Vaccins contre le virus respiratoire
|
|
MA46316A
(fr)
|
2015-10-22 |
2021-03-24 |
Modernatx Inc |
Vaccin contre le cytomégalovirus humain
|
|
CN117731769A
(zh)
|
2015-10-22 |
2024-03-22 |
摩登纳特斯有限公司 |
用于水痘带状疱疹病毒(vzv)的核酸疫苗
|
|
AU2016342376A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Sexually transmitted disease vaccines
|
|
MD3386484T2
(ro)
|
2015-12-10 |
2022-11-30 |
Modernatx Inc |
Compoziții și metode de livrare a unor agenți terapeutici
|
|
KR102608220B1
(ko)
|
2016-05-06 |
2023-11-29 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Glp-1 수용체 리간드 모이어티 컨쥬게이트된 올리고뉴클레오티드 및 이의 용도
|
|
WO2017201342A1
(en)
*
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding jagged1 for the treatment of alagille syndrome
|
|
MA45053A
(fr)
*
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystique
|
|
KR20190026819A
(ko)
|
2016-07-07 |
2019-03-13 |
루비우스 테라퓨틱스, 아이엔씨. |
외인성 rna를 발현하는 치료용 세포 시스템과 관련된 조성물 및 방법
|
|
CN109937253B
(zh)
|
2016-09-14 |
2023-06-30 |
摩登纳特斯有限公司 |
高纯度rna组合物及其制备方法
|
|
WO2018075980A1
(en)
|
2016-10-21 |
2018-04-26 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
US10925958B2
(en)
|
2016-11-11 |
2021-02-23 |
Modernatx, Inc. |
Influenza vaccine
|
|
BR112019010486A2
(pt)
|
2016-11-28 |
2019-09-10 |
Napajen Pharma Inc |
sirna quimicamente modificado
|
|
MA50335A
(fr)
|
2016-12-08 |
2020-08-19 |
Modernatx Inc |
Vaccins à acide nucléique contre des virus respiratoires
|
|
US11384352B2
(en)
|
2016-12-13 |
2022-07-12 |
Modernatx, Inc. |
RNA affinity purification
|
|
EP3595713A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
Respiratory syncytial virus vaccine
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
US11576961B2
(en)
|
2017-03-15 |
2023-02-14 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
US20200030432A1
(en)
|
2017-03-17 |
2020-01-30 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
|
EP3607074A4
(en)
|
2017-04-05 |
2021-07-07 |
Modernatx, Inc. |
REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
|
|
WO2018186704A1
(ko)
*
|
2017-04-06 |
2018-10-11 |
포항공과대학교 산학협력단 |
무항생제 플라스미드 유지 시스템에서 플라스미드 카피 수의 정량적 조절 방법
|
|
US11390854B2
(en)
|
2017-05-09 |
2022-07-19 |
Fundacion Para La Investigacion Medica Aplicada |
Human porphobilinogen deaminase derived proteins and polynucleotides and uses thereof
|
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
|
US11866696B2
(en)
|
2017-08-18 |
2024-01-09 |
Modernatx, Inc. |
Analytical HPLC methods
|
|
US11912982B2
(en)
|
2017-08-18 |
2024-02-27 |
Modernatx, Inc. |
Methods for HPLC analysis
|
|
WO2019036682A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
RNA VARIANTS POLYMERASE
|
|
MX2020002348A
(es)
|
2017-08-31 |
2020-10-08 |
Modernatx Inc |
Métodos de elaboración de nanopartículas lipídicas.
|
|
GB201714430D0
(en)
|
2017-09-07 |
2017-10-25 |
Micol Romain |
Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
|
|
MA50253A
(fr)
|
2017-09-14 |
2020-07-22 |
Modernatx Inc |
Vaccins à arn contre le virus zika
|
|
CN119876131A
(zh)
*
|
2017-11-08 |
2025-04-25 |
Ionis制药公司 |
Glp-1受体配体部分缀合的寡核苷酸及其用途
|
|
WO2019126144A1
(en)
|
2017-12-22 |
2019-06-27 |
North Carolina State University |
Polymeric fluorophores, compositions comprising the same, and methods of preparing and using the same
|
|
US11911453B2
(en)
|
2018-01-29 |
2024-02-27 |
Modernatx, Inc. |
RSV RNA vaccines
|
|
EP4008333A1
(en)
|
2018-02-19 |
2022-06-08 |
Combined Therapeutics, Inc. |
Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
|
|
CA3113025A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Peg lipids and uses thereof
|
|
EP4509118A3
(en)
|
2018-09-19 |
2025-05-14 |
ModernaTX, Inc. |
High-purity peg lipids and uses thereof
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
JP2022521094A
(ja)
|
2019-02-20 |
2022-04-05 |
モデルナティエックス インコーポレイテッド |
共転写キャッピング用ｒｎａポリメラーゼバリアント
|
|
US11851694B1
(en)
|
2019-02-20 |
2023-12-26 |
Modernatx, Inc. |
High fidelity in vitro transcription
|
|
EP3938507A4
(en)
|
2019-03-11 |
2023-02-22 |
ModernaTX, Inc. |
PROCEDURE FOR IN VITRO FED BATCH TRANSCRIPTION
|
|
MA55321A
(fr)
|
2019-03-15 |
2022-01-19 |
Modernatx Inc |
Vaccins à base d'arn contre le vih
|
|
WO2020204130A1
(ja)
*
|
2019-04-05 |
2020-10-08 |
国立大学法人京都大学 |
Ｒｎａのキャッピング方法、修飾ｒｎａの製造方法、及び修飾ｒｎａ
|
|
WO2021001377A1
(en)
|
2019-07-02 |
2021-01-07 |
Fundacion Para La Investigacion Medica Aplicada |
cPLA2e INDUCING AGENTS AND USES THEREOF
|
|
JP2023522249A
(ja)
|
2020-04-22 |
2023-05-29 |
ビオンテック・ソシエタス・エウロパエア |
コロナウイルスワクチン
|
|
WO2022035621A1
(en)
|
2020-07-31 |
2022-02-17 |
Combined Therapeutics, Inc. |
Compositions and methods for improved vaccination
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
US12329811B2
(en)
|
2021-01-11 |
2025-06-17 |
Modernatx, Inc. |
Seasonal RNA influenza virus vaccines
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
US20220363937A1
(en)
|
2021-05-14 |
2022-11-17 |
Armstrong World Industries, Inc. |
Stabilization of antimicrobial coatings
|
|
TW202317766A
(zh)
*
|
2021-06-24 |
2023-05-01 |
南韓商韓美藥品股份有限公司 |
非自然發生的5’-非轉譯區及3’-非轉譯區及其用途
|
|
US20240325426A1
(en)
*
|
2021-06-30 |
2024-10-03 |
Kyowa Kirin Co., Ltd. |
Polynucleotide and pharmaceutical composition
|
|
EP4379055A4
(en)
*
|
2021-07-27 |
2025-08-06 |
Sk Bioscience Co Ltd |
MRNA FOR PROTEIN EXPRESSION AND TEMPLATE FOR IT
|
|
KR20240090727A
(ko)
|
2021-10-22 |
2024-06-21 |
세일 바이오메디슨스, 인크. |
Mrna 백신 조성물
|
|
AU2022398450A1
(en)
|
2021-11-23 |
2024-06-06 |
Sail Biomedicines, Inc. |
A bacteria-derived lipid composition and use thereof
|
|
US12186387B2
(en)
|
2021-11-29 |
2025-01-07 |
BioNTech SE |
Coronavirus vaccine
|
|
JP2025500373A
(ja)
|
2021-12-20 |
2025-01-09 |
セイル バイオメディシンズ インコーポレイテッド |
Ｍｒｎａ治療用組成物
|
|
WO2023177904A1
(en)
|
2022-03-18 |
2023-09-21 |
Modernatx, Inc. |
Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications
|
|
JP2025519096A
(ja)
|
2022-05-25 |
2025-06-24 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
遺伝的ドライバーを調節するための組成物及び方法
|
|
AU2023275550A1
(en)
|
2022-05-25 |
2024-11-21 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulating cytokines
|
|
AU2023276714A1
(en)
|
2022-05-25 |
2024-11-21 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulation of immune responses
|
|
CN119947754A
(zh)
|
2022-05-25 |
2025-05-06 |
旗舰创业创新第七有限责任公司 |
用于调节肿瘤抑制因子和癌基因的组合物和方法
|
|
EP4650780A2
(en)
|
2022-05-25 |
2025-11-19 |
Flagship Pioneering Innovations VII, LLC |
Compositions and methods for modulating circulating factors
|
|
US11878055B1
(en)
|
2022-06-26 |
2024-01-23 |
BioNTech SE |
Coronavirus vaccine
|
|
WO2024035733A1
(en)
*
|
2022-08-08 |
2024-02-15 |
The Curators Of The University Of Missouri |
Fasl-modified plg scaffolds enhances differentiation of stem cell derived beta cells
|
|
EP4577519A1
(en)
|
2022-08-23 |
2025-07-02 |
ModernaTX, Inc. |
Methods for purification of ionizable lipids
|
|
JP2025537750A
(ja)
|
2022-11-10 |
2025-11-20 |
セイル バイオメディシンズ インコーポレイテッド |
脂質ナノ粒子または脂質再構成天然メッセンジャーパックを含むｒｎａ組成物
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
AU2024212425A1
(en)
|
2023-01-27 |
2025-08-07 |
Sail Biomedicines, Inc. |
A modified lipid composition and uses thereof
|
|
WO2024220752A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Rna therapeutic compositions
|
|
WO2024220625A1
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
|
|
WO2024220712A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Vaccine compositions
|
|
WO2024238726A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating methylation of a target gene
|
|
WO2024238723A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating pcsk9 expression
|
|
WO2025019742A1
(en)
|
2023-07-19 |
2025-01-23 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating ctnnb1 expression
|
|
AR133964A1
(es)
*
|
2023-09-27 |
2025-11-19 |
Hanmi Pharmaceutical Co Ltd |
Región no traducida en 5 no natural y uso de la misma
|
|
WO2025194138A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
St1cas9 compositions and methods for modulating a genome
|
|
WO2025235563A1
(en)
|
2024-05-07 |
2025-11-13 |
Omega Therapeutics, Inc. |
Epigenetic modulation for upregulation of genes
|